Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

20102,183 citationsJournal Articlebronze Open Access

Authors

Jeffrey A. Cohen · Cleveland Clinic

Frederik Barkhof · Vrije Universiteit Amsterdam

Gıancarlo Comı · Vita-Salute San Raffaele University

Hans‐Peter Hartung · Heinrich Heine University Düsseldorf

Bhupendra Khatri · Hope Center for Neurological Disorders

Xavier Montalbán · Institute of Neuroimmunology of the Slovak Academy of Sciences

Jean Pelletier

Abstract

This trial showed the superior efficacy of oral fingolimod with respect to relapse rates and MRI outcomes in patients with multiple sclerosis, as compared with intramuscular interferon beta-1a. Longer studies are needed to assess the safety and efficacy of treatment beyond 1 year. (ClinicalTrials.gov number, NCT00340834.)

Topics & Keywords

Multiple Sclerosis Research Studies Peripheral Neuropathies and Disorders Sphingolipid Metabolism and Signaling

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 362, Issue 5, pp. 402-415

DOI: 10.1056/nejmoa0907839

Field-Weighted Citation Impact: 125.58